Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL W SCHUSTER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1669569752
CMS profile
29919
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$167,919.39

183 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL W SCHUSTER

NPI 1669569752 · CMS profile ID 29919

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669569752?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL W SCHUSTER, NPI 1669569752, CMS profile ID 29919. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669569752?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MICHAEL W SCHUSTER, NPI 1669569752, CMS profile ID 29919. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669569752?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MICHAEL W SCHUSTER, NPI 1669569752, CMS profile ID 29919, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1669569752?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

183 matching records · $167,919.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 183 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 183.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $184.3705/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131737394 CMS
PFIZER INC. $4,250.0005/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131737396 CMS
PFIZER INC. $125.0005/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131737410 CMS
PFIZER INC. $25.4605/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131810173 CMS
PFIZER INC. $241.8905/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131811840 CMS
PFIZER INC. $3,275.0005/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131810175 CMS
PFIZER INC. $111.7905/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131815422 CMS
Astellas Pharma US Inc $122.1605/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139379770 CMS
Astellas Pharma US Inc $1,830.4405/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139387540 CMS
Astellas Pharma US Inc $263.4405/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139387542 CMS
Astellas Pharma US Inc $5,100.0005/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139387544 CMS
Incyte Corporation $4,110.0005/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141195405 CMS
Daiichi Sankyo Inc. $29.0805/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089479811 CMS
E.R. Squibb & Sons, L.L.C. $103.8805/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101323248 CMS
E.R. Squibb & Sons, L.L.C. $167.8305/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101323250 CMS
Incyte Corporation $342.5005/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141287530 CMS
Incyte Corporation $23.6704/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141281182 CMS
Incyte Corporation $209.0404/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141213374 CMS
Incyte Corporation $323.5804/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141213390 CMS
Incyte Corporation $123.0604/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141242370 CMS
Incyte Corporation $53.0204/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141289836 CMS
Janssen Biotech, Inc. $4,125.0004/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078441214 CMS
Incyte Corporation $4,110.0004/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141208423 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.3503/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144966863 CMS
E.R. Squibb & Sons, L.L.C. $3,176.0003/27/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101323236 CMS
Incyte Corporation $29.4803/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141255648 CMS
Incyte Corporation $124.9903/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141315597 CMS
Janssen Biotech, Inc. $26.7003/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078440801 CMS
Janssen Biotech, Inc. $115.3103/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078444322 CMS
SOBI, INC $1,850.0003/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141417708 CMS
Astellas Pharma US Inc $125.0003/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139379766 CMS
Astellas Pharma US Inc $4,820.0003/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139387546 CMS
Astellas Pharma US Inc $676.5403/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139387548 CMS
Janssen Biotech, Inc. $4,125.0003/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078440833 CMS
Janssen Biotech, Inc. $628.1703/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078454453 CMS
Janssen Biotech, Inc. $60.0003/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078439829 CMS
Janssen Biotech, Inc. $79.9603/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078440969 CMS
Janssen Biotech, Inc. $39.9903/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078445785 CMS
Janssen Biotech, Inc. $39.9903/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078445849 CMS
Janssen Biotech, Inc. $60.0003/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078447878 CMS
Janssen Biotech, Inc. $39.9903/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078448599 CMS
Janssen Biotech, Inc. $79.9603/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078451027 CMS
Janssen Biotech, Inc. $39.9903/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078453828 CMS
Janssen Biotech, Inc. $79.9603/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078454457 CMS
Janssen Biotech, Inc. $60.0003/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078457976 CMS
Janssen Biotech, Inc. $60.0003/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078458209 CMS
Janssen Biotech, Inc. $79.9603/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078458622 CMS
Janssen Biotech, Inc. $147.6203/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078441139 CMS
Janssen Biotech, Inc. $150.0003/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078441513 CMS
Janssen Biotech, Inc. $150.0003/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078442242 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $386,385.21 367
PY2020 $190,315.03 123
PY2021 $167,429.38 129
PY2022 $287,607.10 229
PY2023 $254,531.04 200
PY2024 $167,919.39 183
PY2025 $120,496.30 125

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,672.47 11
PY2025 Principal investigator $1,029,265.41 203
PY2024 Principal investigator $285,981.04 71
PY2023 Principal investigator $184,796.16 87
PY2022 Recipient $780.00 1
PY2022 Principal investigator $38,774.14 13
PY2021 Recipient $4,600.00 2
PY2021 Principal investigator $42,907.79 22
PY2020 Recipient $1,270.00 2
PY2020 Principal investigator $97,848.17 25
PY2019 Principal investigator $264,201.51 60

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

214 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,438.10 12/22/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184279514
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,438.10 12/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184278340
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $357.30 12/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184278342
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $357.30 12/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184278344
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,952.20 12/19/2025 Non-covered Recipient Entity
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA No dispute reported 06/30/2026 1184278800
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $177.00 12/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184276962
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $694.00 12/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184276964
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.00 12/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184276966
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.00 12/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184276968
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $177.00 12/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184276970
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $177.00 12/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184276972
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $347.00 12/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184276974
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.00 12/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184276976
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $177.00 12/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184276978
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $347.00 12/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184276980
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.00 12/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184276982
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $347.00 12/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184276984
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $177.00 12/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184276986
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.00 12/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184276988
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,225.10 12/11/2025 Non-covered Recipient Entity
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA No dispute reported 06/30/2026 1184274256
Principal investigator 1 Incyte Corporation $4,332.00 12/10/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596914
Principal investigator 1 Incyte Corporation $2,192.00 12/10/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596917
Principal investigator 1 Incyte Corporation $2,961.00 12/10/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596934
Recipient Regeneron Pharmaceuticals, Inc. $1,259.44 12/07/2025 Covered Recipient Physician PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122261
Recipient Regeneron Pharmaceuticals, Inc. $279.85 12/05/2025 Covered Recipient Physician PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122249
Recipient Regeneron Pharmaceuticals, Inc. $309.06 12/05/2025 Covered Recipient Physician PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122251
Recipient Regeneron Pharmaceuticals, Inc. $78.97 12/05/2025 Covered Recipient Physician PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122253
Recipient Regeneron Pharmaceuticals, Inc. $33.55 12/05/2025 Covered Recipient Physician PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122255
Recipient Regeneron Pharmaceuticals, Inc. $59.56 12/05/2025 Covered Recipient Physician PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122257
Recipient Regeneron Pharmaceuticals, Inc. $19.26 12/05/2025 Covered Recipient Physician PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.00 12/05/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184269637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $347.00 12/05/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184269639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $347.00 12/05/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184269641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $177.00 12/05/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184269643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $347.00 12/05/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184269645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $177.00 12/05/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184269647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.00 12/05/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184269649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,438.10 11/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184265821
Principal investigator 1 Incyte Corporation $2,285.40 11/21/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596905
Principal investigator 1 Incyte Corporation $3,071.00 11/21/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596922
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $455.00 11/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184262197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,820.00 11/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184262199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,306.90 11/14/2025 Non-covered Recipient Entity
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA No dispute reported 06/30/2026 1184261085
Principal investigator 1 Incyte Corporation $4,024.00 11/12/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596902
Principal investigator 1 Incyte Corporation $4,698.00 11/12/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596910
Principal investigator 1 Incyte Corporation $4,020.00 11/12/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596925
Principal investigator 1 Incyte Corporation $2,479.00 11/12/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596930
Principal investigator 1 Incyte Corporation $161.80 11/10/2025 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240597204
Principal investigator 1 Incyte Corporation $114.50 11/10/2025 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240597209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,900.80 11/06/2025 Non-covered Recipient Entity
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA No dispute reported 06/30/2026 1184257727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,030.00 10/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184253366
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,030.00 10/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184253368
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,060.00 10/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184253370
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,030.00 10/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184253372
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,030.00 10/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184253374
Recipient Regeneron Pharmaceuticals, Inc. $319.01 10/16/2025 Covered Recipient Physician PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,008.60 10/13/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184249929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,008.60 10/13/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184249931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25,223.90 10/09/2025 Non-covered Recipient Entity
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA No dispute reported 06/30/2026 1184248850
Recipient Regeneron Pharmaceuticals, Inc. $390.92 10/03/2025 Covered Recipient Physician PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184122245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,811.60 10/03/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184245825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,819.10 10/01/2025 Non-covered Recipient Entity
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA No dispute reported 06/30/2026 1184244451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $799.20 09/29/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184243887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,513.80 09/29/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184243889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 09/24/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184242285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,483.00 09/24/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184242287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 09/24/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184242289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,483.00 09/24/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184242291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 09/24/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184242293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 09/24/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184242295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 09/24/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184242297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 09/24/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184242299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 09/24/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184242301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $347.00 09/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184240892
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $177.00 09/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184240894
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.00 09/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184240896
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.00 09/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184240898
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $177.00 09/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184240900
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $242.00 09/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184240902
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.00 09/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184240904
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $177.00 09/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184240906
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.00 09/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184240908
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.00 09/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184240910
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $177.00 09/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184240912
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,041.00 09/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184240914
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $242.00 09/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184240916
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $177.00 09/19/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184240918
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,851.00 09/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184238410
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $423.00 09/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184238412
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $423.00 09/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184238414
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,851.00 09/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184238416
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,820.00 09/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184238418
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $423.00 09/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184238420
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,851.00 09/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184238422
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $455.00 09/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184238424
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,851.00 09/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184238426
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $423.00 09/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184238428
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $658.00 09/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184238430
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $658.00 09/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184238432
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $658.00 09/17/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184238434
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,827.90 08/28/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184231289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,513.80 08/28/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184231291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,513.80 08/28/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184231293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,732.40 08/28/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184231295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,513.80 08/28/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184231363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $221.00 08/21/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184229523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $335.40 08/21/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184229525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $177.00 08/21/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184229527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $177.00 08/21/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184229529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,176.70 08/21/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184229533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,176.70 08/21/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184229535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,176.70 08/21/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184229543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,176.70 08/21/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184229545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,176.70 08/21/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184229547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,810.00 08/21/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184229551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,810.00 08/21/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184229553
Principal investigator 1 Incyte Corporation $2,300.00 08/20/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596870
Principal investigator 1 Incyte Corporation $5,000.00 08/20/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596874
Principal investigator 1 Incyte Corporation $780.00 08/20/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596877
Principal investigator 1 Incyte Corporation $1,000.00 08/20/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596882
Principal investigator 1 Incyte Corporation $1,500.00 08/20/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596885
Principal investigator 1 Incyte Corporation $10,000.00 08/20/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596889
Principal investigator 1 Incyte Corporation $1,000.00 08/20/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596893
Principal investigator 1 Incyte Corporation $1,500.00 08/20/2025 Non-covered Recipient Entity
STATE UNIVERSITY OF NEW YORK
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240596897
Principal investigator 1 Incyte Corporation $16.18 08/08/2025 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240597220
Principal investigator 1 Incyte Corporation $45.80 08/08/2025 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240597227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,438.10 07/30/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184221900
Principal investigator 1 Incyte Corporation $48.54 07/09/2025 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240597213
Principal investigator 1 Incyte Corporation $29.39 07/09/2025 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240597217
Principal investigator 1 Incyte Corporation $45.80 07/09/2025 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER
A study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 1240597225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,810.00 06/30/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184212233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,810.00 06/30/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184212235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,672.40 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210918
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,672.40 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210920
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,672.40 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210922
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,672.40 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210924
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,672.40 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210926
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,672.40 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210928
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,672.40 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210930
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,672.40 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210932
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,672.40 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210934
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,672.40 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210936
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,672.40 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210938
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,672.40 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210940
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,672.40 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210942
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,672.40 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210944
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,672.40 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210946
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,176.70 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210948
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,176.70 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210950
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,176.70 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210952
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,176.70 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210954
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,176.70 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210956
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,176.70 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210958
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25,344.80 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210960
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25,344.80 06/25/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184210962
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,827.90 06/18/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184208631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,438.10 06/18/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184208671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,493.00 06/18/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184208677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,493.00 06/18/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184208679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,732.40 06/18/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184208695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,811.60 06/18/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184208701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,448.80 06/18/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184208771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,448.80 06/18/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184208773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,822.30 06/18/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184208787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,435.20 06/18/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184208799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,515.30 06/18/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184208807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,918.50 06/18/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184208809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,212.80 06/18/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184208811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,292.00 06/18/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184208813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 06/02/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184200873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 06/02/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184200875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $72,540.00 06/02/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184202907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,083.40 04/23/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184186937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 04/10/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184182882
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 04/10/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184182884
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $975.00 04/10/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184182886
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $975.00 04/10/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184182888
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $975.00 04/10/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184182890
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 04/10/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184182892
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 04/10/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184182894
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $975.00 04/10/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184182896
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,493.00 02/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184156074
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,212.80 02/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184156076
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,141.80 02/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184156078
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,493.00 02/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184156080
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,292.00 02/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184156082
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,132.00 02/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184156084
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,292.00 02/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184156086
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,918.50 02/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184156088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,212.80 02/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184156090
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,493.00 02/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184156092
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,355.30 02/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184156094
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,515.30 02/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184156096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,355.30 02/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184156098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,355.30 02/27/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184156100
Recipient GlaxoSmithKline, LLC. $31.02 02/25/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI No dispute reported 06/30/2026 1192165211
Recipient GlaxoSmithKline, LLC. $891.83 02/25/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF BELANTAMAB MAFODOTIN ADMI No dispute reported 06/30/2026 1192165215
Principal investigator 1 Celgene Corporation $10,000.00 02/20/2025 Non-covered Recipient Entity
Research Foundation Of Suny
A Study to Evaluate the Efficacy and Safety of Lisocabtagene Maraleucel Monotherapy Compared to Investigators Choice Options (Idelalisib + Rituximab or Bendamustine + Rituximab) in Adult Participants with Double Class Exposed Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) No dispute reported 06/30/2026 1222304939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,775.50 02/12/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,874.60 02/12/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153662
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,874.60 02/12/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153664
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,874.60 02/12/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,874.60 02/12/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,874.60 02/12/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,775.50 02/12/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153672
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,874.60 02/12/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184153674
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,093.00 01/08/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184146410
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 01/08/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184146412
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $780.00 01/08/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184146414
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,300.00 01/08/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184146416
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,500.00 01/08/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184146418
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,000.00 01/08/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184146420
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,496.00 01/08/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184146422
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,570.00 01/08/2025 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
PHASE 1/2 STUDY OF LINVOSELTAMAB (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PREVIOUSLY UNTREATED PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA No dispute reported 06/30/2026 1184146424